Literature DB >> 25588997

Theranostic mercury: (197(m))Hg with high specific activity for imaging and therapy.

Martin Walther1, Stephan Preusche1, Stig Bartel2, Gerd Wunderlich3, Robert Freudenberg3, Jörg Steinbach1, Hans-Jürgen Pietzsch1.   

Abstract

The no carrier added (NCA) radionuclide (197(m))Hg is accessible through proton induced nuclear reactions on gold. The decay properties of both simultaneous produced nuclear isomers (197m)Hg and (197)Hg like convenient half life, low energy gamma radiations for imaging, Auger and conversion electrons for therapy are combined with unique chemical and physical properties of mercury and its compounds. Gold as a monoisotopic element has a natural abundance of 100% (197)Au superseding expensive enrichment for the target material. Additionally, the high thermal conductivity of gold enables high beam current irradiations. For separation of target material a liquid-liquid extraction method was applied.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  (177)Lu; (197)Hg; Auger and conversion electrons; Dosimetry; Theranostics

Year:  2015        PMID: 25588997     DOI: 10.1016/j.apradiso.2015.01.001

Source DB:  PubMed          Journal:  Appl Radiat Isot        ISSN: 0969-8043            Impact factor:   1.513


  3 in total

1.  Meitner-Auger Electron Emitters for Targeted Radionuclide Therapy: Mercury-197m/g and Antimony-119

Authors:  Parmissa Randhawa; Aeli P Olson; Shaohuang Chen; Kaley Lexi Gower-Fry; Cornelia Hoehr; Jonathan W Engle; Caterina F Ramogida; Valery Radchenko
Journal:  Curr Radiopharm       Date:  2021

2.  Molecular imaging using the theranostic agent 197(m)Hg: phantom measurements and Monte Carlo simulations.

Authors:  Robert Freudenberg; Rudi Apolle; Martin Walther; Holger Hartmann; Jörg Kotzerke
Journal:  EJNMMI Phys       Date:  2018-08-27

3.  Radiolabelled Cyclic Bisarylmercury: High Chemical and in vivo Stability for Theranostics.

Authors:  Ian Moore F Gilpin; Martin Ullrich; Thomas Wünsche; Kristof Zarschler; Ondřej Lebeda; Jens Pietzsch; Hans-Jürgen Pietzsch; Martin Walther
Journal:  ChemMedChem       Date:  2021-06-16       Impact factor: 3.466

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.